HomeCompareTBPMF vs GBDC

TBPMF vs GBDC: Dividend Comparison 2026

TBPMF yields 222222.22% · GBDC yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBPMF wins by $1.4076447531278624e+30M in total portfolio value
10 years
TBPMF
TBPMF
● Live price
222222.22%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4076447531278624e+30M
Annual income
$1,406,399,782,569,334,400,000,000,000,000,000,000.00
Full TBPMF calculator →
GBDC
GBDC
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full GBDC calculator →

Portfolio growth — TBPMF vs GBDC

📍 TBPMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBPMFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBPMF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TBPMF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBPMF
Annual income on $10K today (after 15% tax)
$18,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, TBPMF beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBPMF + GBDC for your $10,000?

TBPMF: 50%GBDC: 50%
100% GBDC50/50100% TBPMF
Portfolio after 10yr
$7.038223765639312e+29M
Annual income
$703,199,891,284,667,200,000,000,000,000,000,000.00/yr
Blended yield
99.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

TBPMF
No analyst data
Altman Z
-75.5
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
-72.0% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBPMF buys
0
GBDC buys
0
No recent congressional trades found for TBPMF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBPMFGBDC
Forward yield222222.22%4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR0%5%
Portfolio after 10y$1.4076447531278624e+30M$28.0K
Annual income after 10y$1,406,399,782,569,334,400,000,000,000,000,000,000.00$899.19
Total dividends collected$1.4075632434891558e+30M$6.4K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TBPMF vs GBDC ($10,000, DRIP)

YearTBPMF PortfolioTBPMF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$22,232,922$22,222,222.22$11,120$420.00+$22.22MTBPMF
2$46,198,082,523$46,174,293,296.41$12,357$458.31+$46198.07MTBPMF
3$89,718,752,943,223$89,669,320,994,923.30$13,721$499.76+$89718752.93MTBPMF
4$162,845,393,609,755,680$162,749,394,544,106,430.00$15,227$544.58+$162845393609.74MTBPMF
5$276,249,735,879,778,500,000$276,075,491,308,616,120,000.00$16,885$593.02+$276249735879778.47MTBPMF
6$437,989,462,258,048,500,000,000$437,693,875,040,657,100,000,000.00$18,713$645.34+$437989462258048512.00MTBPMF
7$649,026,142,700,674,900,000,000,000$648,557,493,976,058,700,000,000,000.00$20,724$701.81+$649026142700674875392.00MTBPMF
8$898,874,153,179,794,200,000,000,000,000$898,179,695,207,104,400,000,000,000,000.00$22,938$762.73+$8.988741531797941e+23MTBPMF
9$1,163,523,886,474,633,300,000,000,000,000,000$1,162,562,091,130,731,000,000,000,000,000,000.00$25,372$828.41+$1.1635238864746333e+27MTBPMF
10$1,407,644,753,127,862,300,000,000,000,000,000,000$1,406,399,782,569,334,400,000,000,000,000,000,000.00$28,047$899.19+$1.4076447531278624e+30MTBPMF

TBPMF vs GBDC: Complete Analysis 2026

TBPMFStock

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Full TBPMF Calculator →

GBDCBDC

GBDC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in GBDC shares.

Full GBDC Calculator →
📬

Get this TBPMF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBPMF vs SCHDTBPMF vs JEPITBPMF vs OTBPMF vs KOTBPMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.